Overseas Contractor Bill Could Give Pharma Federal Contracting Headaches In U.S.
This article was originally published in PharmAsia News
Executive Summary
A U.S. House-passed bill that would bar firms from federal contracts if they violate the Foreign Corrupt Practices Act could put any violative pharma firms at risk of losing participation in drug benefit programs with the Department of Veterans Affairs, Medicaid and Medicare